1035219-17-0

Basic information

• Product Name: 5-[4-(azetidin-3-yloxy)-3-methoxyphenyl]-2-(4-chlorophenyl)-6,7-dihydro-5H-thiazolo[5,4-c]pyridin-4-one
• Synonyms: 5-[4-(azetidin-3-yloxy)-3-methoxyphenyl]-2-(4-chlorophenyl)-6,7-dihydro-5H-thiazolo[5,4-c]pyridin-4-one
• CAS NO: 1035219-17-0
• Molecular Weight: 441.938
• Mol File: 1035219-17-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 5-[4-(azetidin-3-yloxy)-3-methoxyphenyl]-2-(4-chlorophenyl)-6,7-dihydro-5H-thiazolo[5,4-c]pyridin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-[4-(azetidin-3-yloxy)-3-methoxyphenyl]-2-(4-chlorophenyl)-6,7-dihydro-5H-thiazolo[5,4-c]pyridin-4-one(1035219-17-0)
• EPA Substance Registry System: 5-[4-(azetidin-3-yloxy)-3-methoxyphenyl]-2-(4-chlorophenyl)-6,7-dihydro-5H-thiazolo[5,4-c]pyridin-4-one(1035219-17-0)

Safety Data

• Hazardous Substances Data: 1035219-17-0(Hazardous Substances Data)

Upstream product

• 1035219-61-4 3-{4-[2-(4-chlorophenyl)-4-oxo-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]-2-methoxyphenoxy}azetidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1035219-19-2 2-(4-chlorophenyl)-5-[3-methoxy-4-(1-methylazetidin-3-yloxy)phenyl]-6,7-dihydro-5H-thiazolo[5,4-c]pyridin-4-one 
• 1035219-18-1 5-[4-(azetidin-3-yloxy)-3-methoxyphenyl]-2-(4-chlorophenyl)-6,7-dihydro-5H-thiazolo[5,4-c]pyridin-4-one hydrochloride 
• 1035219-21-6 2-(4-chlorophenyl)-5-[4-(1-isopropylazetidin-3-yloxy)-3-methoxyphenyl]-6,7-dihydro-5H-thiazolo[5,4-c]pyridin-4-one hydrochloride 

Relevant articles and documents

5- [4- (AZETIDIN-3-YL0XY) -PHENYL] -2-PHENYL-5H-THIAZ0L0 [5,4-C] PYRIDIN-4-0NE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS

The present invention relates to a melanin concentrating hormone antagonist compound of formula I: wherein "-----" is absent or is optionally a bond; q is 1 or 2; R1 is independently selected from hydrogen, -C1-C2 alkyl, halo, hydroxy, -C1-C2 haloalkyl, -C1-C3 alkoxy, cyano, -O-C3-C4 cycloalkyl, and -OC1-C2 haloalkyl; R2 is selected from the group consisting of hydrogen, -C1-C3 alkyl, hydroxy, -C1-C3 alkoxy, cyano, -C1-C2 haloalkyl, -OC1-C2 haloalkyl, and halo; R3 is selected from the group consisting of hydrogen, -C1-C4 alkyl, -C2-C4 haloalkyl, -C2-C4 alkylOH, -C3-C6 cycloalkyl, -CH2C3-C6 cyxloalkyl, -C2-C4 alkyl-O-C1-C4 alkyl, -C(O)C1-C4 alkyl, -C(O)C1-C4 haloalkyl, -CH2-thiazole, phenyl, benzyl, tetrahydrothiopyranyl, and tetrahydropyranyl, wherein the cycloalkyl, tetrahydrothiopyranyl, tetrahydropyranyl and thiazolyl group is optionally substituted with one or two groups independently selected from the group consisting of halo, hydroxy, C1-C2 alkyl, and -C1-C2 haloalkyl; or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof,, useful in the treating, preventing or ameliorating of symptoms associated with obesity and related diseases.